Angle plc Stock
€0.12
Your prediction
Pros and Cons of Angle plc in the next few years
Pros
Cons
Performance of Angle plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Angle plc | -12.950% | 15.833% | -15.758% | -27.225% | 23.009% | -85.368% | - |
| Byotrol plc | - | 0.000% | 0.000% | -95.652% | -85.714% | -99.225% | - |
| Proteome Sciences | - | 0.000% | 0.000% | 33.333% | 6.667% | -15.789% | 166.667% |
| Oxford BioMedica PLC | -2.540% | -1.667% | 13.462% | -51.837% | -3.279% | -80.496% | -70.720% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance at the financials of Angle, a company in the Biotechnology & Medical Research industry, it appears that it is a company with a few key strengths but also some areas that need improvement to stay competitive in the industry. It has a healthy balance of assets and liabilities, but also a considerable loss on the income statements. This provides an intriguing starting point to analyze the overall performance of the company.
Strong Cash Position: Over the years, Angle has progressively built up its cash position, allowing it to invest in new opportunities, research and development, and working capital for its ongoing operations. As of 2022-04-30, the company had a cash balance of €31,839,000, compared to €12,080,000 in 2021-04-30 and €3,757,000 in 2020-04-30.
Healthy Working Capital: The company's net working capital has been on a positive trajectory, increasing from €29,153,000 in 2021 to €34,454,000 in 2022. This indicates that Angle can cover its short-term obligations without experiencing significant liquidity issues.